The Business Research Company’s report on the Amusement Parks Global Market Report 2025 Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the adult malignant glioma therapeutics market in recent years?
The growing cases of brain tumors are expected to drive the adult malignant glioma therapeutics market growth. A brain tumor is an abnormal mass of tissue in which the normal systems that regulate cells appear not to affect the uncontrollable growth and multiplication of the cells. Adult malignant glioma is a type of brain tumor made up of cells that grow abnormally and uncontrollably. Adult malignant glioma treatment treats brain tumors by combining surgery, radiation therapy, and chemotherapy. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of brain and nervous system cancer cases increased to 24,810 in 2023, reflecting a growth of 3.85% from 23,890 in 2020. Therefore, the growing cases of brain tumors are driving the adult malignant glioma therapeutics market.
Adult Malignant Glioma Therapeutics Market Driver: Government Funding Catalyzing Advancements In Adult Malignant Glioma Therapeutics
Government funding to support brain cancer research is expected to propel the growth of the adult malignant glioma therapeutics market going forward. Government funding refers to the financial support provided by a government entity, whether at the federal, state, or local level, to various organizations, initiatives, projects, programs, or individuals. Government funding to support brain cancer research can be helpful for adult malignant glioma therapeutics by supporting the development of novel treatments, customized drug development, targeting pyrimidine synthesis, and orphan drug approval. For instance, in June 2023, the Australian Department of Health and Aged Care, an Australia-based government authority, initiated the Australian Brain Cancer Mission with a fund of $136.66 million to support research into brain cancer. The initiative aims to double the survival rates and thereby improve the quality of life of patients with brain cancer, including anaplastic astrocytoma. Therefore, government funding to support brain cancer research drives the adult malignant glioma therapeutics market.
Access Your Free Sample of the Global Amusement Parks Global Market Report 2025 Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp
What is the projected market size of the adult malignant glioma therapeutics industry, and how is it expected to grow?
The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.25 billion in 2024 to $2.48 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches.
The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.55 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp
Who are the key players driving competition in the adult malignant glioma therapeutics market?
Major companies operating in the adult malignant glioma therapeutics market report are Johnson & Johnson Private Limited, Pfizer Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Allergan PLC, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Abbott Laboratories, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genetech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.
What key trends are expected to drive the adrenal cancer diagnostics market during the forecast period?
Major companies operating in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to provide reliable customer service. A small-molecule targeted degrader is a drug that uses small molecules to induce the degradation of specific proteins by targeting the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a Sweden-based precision oncology company, received orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). It is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST that has been implicated in the pathogenesis of various cancers, including GBM. BEA-17 works by degrading LSD1 and CoREST, which leads to the reactivation of tumor suppressor genes and the inhibition of cancer cell growth.
Which key geographies are driving the growth of the adult malignant glioma therapeutics market?
North America was the largest region in the adult malignant glioma therapeutics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Order Your Report Now For Swift Delivery
What are the key segments driving growth in the adult malignant glioma therapeutics market?
The adult malignant glioma therapeutics market covered in this report is segmented –
1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users
Subsegments:
1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies
2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies
3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies
4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies
5) By Other Types: Rare Gliomas, Emerging Therapies
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13178
How is the adult malignant glioma therapeutics market defined, and what are its core characteristics?
An adult malignant glioma is a type of brain tumor that originates in the glial cells of the brain or spinal cord. Adult malignant glioma therapeutics refers to the various treatment options available for malignant gliomas in adults, aiming to improve quality of life and prolong survival.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
